Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Stockholders Equity of $411.10 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $411.10M | +330.1% |
| 2024 | -$178.64M | -54.5% |
| 2023 | -$115.64M | -528496.2% |
| 2022 | -$21.9K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $446.70M | +380.6% | +296.2% |
| June 30, 2025 | -$227.73M | -58.8% | -13.8% |
| March 31, 2025 | -$200.03M | -55.2% | -12.0% |
| December 31, 2024 | -$178.64M | -54.5% | -12.2% |
| September 30, 2024 | -$159.21M | -727636.9% | -11.0% |
| June 30, 2024 | -$143.44M | -655570.3% | -11.3% |
| March 31, 2024 | -$128.87M | -588947.9% | -11.4% |
| December 31, 2023 | -$115.64M | -528496.2% | -528496.2% |
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +330.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, BridgeBio Oncology Therapeutics, Inc.’s stockholders equity has grown by 1879224.2% (from -$21.9 thousand to $411.10 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: